Our current trials
Description
A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of VE303 for Prevention of Recurrent Clostridioides difficile Infection: The RestoratiVE303 Study
A Phase III, Multicentre, Randomised, Double-blind,
Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the
Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic
Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations
A randomized, double-blind, placebo- controlled,
multicenter phase III study to evaluate the efficacy and safety of ABX464 once
daily for induction treatment in subjects with moderately to severely active
ulcerative colitis
A Phase 2a Multicenter, Randomized, Platform Study of
Targeted Therapies for the Treatment of Adult Subjects with Moderate to Severe
Crohn's Disease
A Multicenter, Randomized, Double-blind,
Placebo-controlled, Phase 3 Study to Evaluate theEfficacy, Safety, and
Tolerability of BMS-986278 in Participants with Progressive PulmonaryFibrosis
A Multicenter, Randomized, Double-blind,
Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and
Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis
A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab (ABT-981) in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa
A Multicentre, Randomised, Double-Blind,
Parallel Group, Active-Controlled, Phase 3b Study to Evaluate the Efficacy and
Safety of Benralizumab 30mg SC in Eosinophilic Asthma Patients Uncontrolled on
Medium-Dose Inhaled Corticosteroid Plus Long-acting β2-Agonist
In open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis
A multi-country, prospective, post-marketing study of UPadacitinib evaluating speed of onset and durability of effectiveness for patients with moderate to severe Crohn’s disease for 3 years in real-world clinical practice
Endoscopic screening of 50 – 74 year olds for pre-cancerous and cancerous lesions. Towards Gastric Cancer Screening Implementation in the European Union
Randomized, open-label, multicenter phase 3 study to assess the efficacy and safety of GIVinostat versus hydroxyurea IN JAK2V617F-positive high-risk Polycythemia Vera patients
A Phase 3 Randomized, Double-Blinded, Placebo-Controlled Multicentre Trial with Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjögren’s Disease
A 52-Week, Open-Label Evaluation of the Long-term Efficacy and Safety of Single and Repeated Treatments with Methylone for the Treatment of PTSD
Efficacy and safety of COMP360 psilocybin therapy in
Anorexia Nervosa: a proof-of-concept study
A phase III, multicentre, randomised, double-blind, controlled study to investigate the efficacy, safety and tolerability of two initial administrations of COMP360 in participants with treatment-resistant depression
A Phase 2/3, Randomized, Double-Blinded, PlaceboControlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome
Location
Drogheda
Drogheda and Dublin
Mulligar, Dublin, Drogehda, Portiuncular
Mullingar, Dublin, Drogheda, Portinucular and Letterkenny
Drogheda and Dublin
Drogheda and Dublin
Drogheda
Drogheda, Dublin and Portiuncular
Dublin
Dublin
Dublin
Dublin
Dublin
Multiple sites
Dublin and Galway
Dublin
Dublin
Manorhamilton
Manorhamilton
Status
Active and currently recruiting
Active, closed to recruiting
Active, closed to recruiting
Active and recruiting
Active and recruiting
Active and recruiting
Active and recruiting
Active and recruiting
Active, closed to recruiting
Active, closed to recruiting
Active and recruiting
Active and recruiting
Active and recruiting
Active, closed to recruiting
Active, closed to recruiting
Active and recruiting
Active, closed to recruiting